乳腺癌（BC）是癌症的主要原因之一，也是全世界女性恶性肿瘤死亡的首要原因。新的癌症疗法每年都会获得监管机构的批准，为了避免社会健康差异，卫生系统面临着调整其基础设施、方法和报销政策的挑战，以允许广泛获得这些治疗。此外，倾听患者关于治疗偏好的声音也很重要。我们的目的是调查 HER2 阳性 BC 患者和医疗保健专业人员 (HCP) 的给药途径偏好 [皮下 (SC) 或静脉注射 (IV)]，并调查每种给药途径 (SC) 的医疗资源利用率（质量和数量）我们使用 PubMed (MEDLINE)、Cochrane Library、Virtual Health Library (VHL)、Science Electronic Library Online (SciELO) 和 Latin 进行了系统性文献综述，重点关注临床试验以及观察性和经济研究美国和加勒比健康科学文献 (LILACS) 数据库基于系统评价和荟萃分析的首选报告项目 (PRISMA) 声明。文献综述包括 25 项研究的分析。研究报告称，与静脉注射相比，患者和医护人员更喜欢皮下注射给药途径，因为它可以节省就诊时间、给药和准备时间，并且疼痛较少。此外，在分析直接和间接成本时，SC 管理可能是一种更节省成本的选择。由于 BC 是一个重大的全球健康问题，也是全世界女性癌症相关死亡的主要原因，因此了解患者和 HCP 的偏好并将其纳入其中给药途径的选择变得至关重要。观察到的对 SC 给药的偏好不仅符合调整卫生系统以促进广泛获得新癌症疗法的必要性，而且还强调了在制定治疗策略时考虑患者体验和经济影响的重要性。这些见解对于医疗保健政策制定者、临床医生和利益相关者优化医疗保健资源和提高 BC 护理的整体质量至关重要。版权所有 © 2024 Landeiro、Martins、Grigolon、Monteiro、Balardin、Padilha、Amorim 和 Stefani。

Breast cancer (BC) is one of the leading causes of cancer and is the first cause of death from malignant tumors among women worldwide. New cancer therapies receive regulatory approval yearly and to avoid health disparities in society, the health systems are challenged to adapt their infrastructure, methodologies, and reimbursement policies to allow broad access to these treatments. In addition, listening to patients' voices about their therapy preferences is essential. We aim to investigate the administration route preferences [subcutaneous (SC) or intravenous (IV)] among patients diagnosed with HER2 positive BC and healthcare professionals (HCPs) and to investigate healthcare resources utilization (quality and quantity) for each route of administration (SC or IV) for treating those patients.We conducted a systematic literature review focused on clinical trials and observational and economic studies, using PubMed (MEDLINE), Cochrane Library, Virtual Health Library (VHL), Scientific Electronic Library Online (SciELO), and Latin American and Caribbean Health Sciences Literature (LILACS) databases based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.The literature review included 25 studies in the analysis. Studies have reported that patients and HCPs prefer the SC route of administration to IV because it saves time in terms of chair time, administration, and preparation and is less painful. In addition, SC administration might be a more cost-saving option when analyzing direct and indirect costs.As BC stands as a significant global health concern and the leading cause of cancer-related deaths in women worldwide, understanding and incorporating patient and HCPs preferences in the choice of administration route become paramount. The observed preference for SC administration not only aligns with the imperative of adapting health systems to facilitate broad access to new cancer therapies but also underscores the importance of considering patient experiences and economic implications in shaping treatment strategies. These insights are crucial for healthcare policymakers, clinicians, and stakeholders in optimizing healthcare resources and enhancing the overall quality of BC care.Copyright © 2024 Landeiro, Martins, Grigolon, Monteiro, Balardin, Padilha, Amorim and Stefani.